WINTON GROUP Ltd Purchases New Position in Organon & Co. $OGN

WINTON GROUP Ltd purchased a new stake in Organon & Co. (NYSE:OGN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 509,862 shares of the company’s stock, valued at approximately $6,904,000.

Several other hedge funds have also bought and sold shares of OGN. Allied Private Wealth LLC purchased a new position in shares of Organon & Co. during the 2nd quarter valued at approximately $33,000. Nykredit A S purchased a new stake in Organon & Co. during the second quarter worth $76,000. GAMMA Investing LLC boosted its holdings in Organon & Co. by 69.8% during the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock worth $78,000 after buying an additional 2,376 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in Organon & Co. during the fourth quarter valued at $44,000. Finally, Kestra Advisory Services LLC acquired a new stake in Organon & Co. during the fourth quarter valued at $47,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Organon & Co. stock opened at $13.69 on Thursday. The stock has a market capitalization of $3.59 billion, a P/E ratio of 17.77, a P/E/G ratio of 1.27 and a beta of 1.52. The company’s fifty day moving average price is $13.63 and its 200 day moving average price is $11.47. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95. Organon & Co. has a 1 year low of $5.69 and a 1 year high of $13.78.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $0.02 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 10.39%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Organon & Co. presently has an average rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.